On the public citation graph

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

https://doi.org/10.1093/annonc/mdn169
0 signed · 1198 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archotol.1995.01890110041008openalex-snapshot
HER-2/neu Oncogene Characterization in Head and Neck Squamous Cell Carcinoma
inferredcites →https://doi.org/10.1002/(sici)1097-0142(19990501)85:9%3c1894::aid-cncr3%3e3.0.co;2-jopenalex-snapshot
The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas
inferredcites →https://doi.org/10.1002/(sici)1098-1004(1998)12:4<226::aid-humu2>3.0.co;2-dopenalex-snapshot
Mutations of the human E-cadherin (CDH1) gene
inferredcites →https://doi.org/10.1002/1097-0142(19930615)71:12<3942::aid-cncr2820711224>3.0.co;2-3openalex-snapshot
Serum levels of HER-2neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer
inferredcites →https://doi.org/10.1002/1097-0142(19931001)72:7<2083::aid-cncr2820720705>3.0.co;2-1openalex-snapshot
Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer
inferredcites →https://doi.org/10.1002/1097-0142(19931201)72:11<3179::aid-cncr2820721108>3.0.co;2-#openalex-snapshot
Overexpression of c‐ erb B‐2 protein in gastric cancer. Its correlation with long‐term survival of patients
inferredcites →https://doi.org/10.1002/1097-0142(19950315)75:6+<1418::aid-cncr2820751505>3.0.co;2-yopenalex-snapshot
Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbb-2 in human gastric cancer
inferredcites →https://doi.org/10.1002/ijc.10257openalex-snapshot
Status of c‐erbB‐2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme‐linked immuno‐sorbent assay
inferredcites →https://doi.org/10.1002/j.1460-2075.1993.tb05891.xopenalex-snapshot
A novel transcription factor, OB2‐1, is required for overexpression of the proto‐oncogene c‐erbB‐2 in mammary tumour lines.
inferredcites →https://doi.org/10.1002/jso.2930490402openalex-snapshot
Clinicopathological significance of c‐erbB‐2 protein expression in human gastric carcinoma
inferredcites →https://doi.org/10.1007/s00280-006-0337-zopenalex-snapshot
Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models
inferredcites →https://doi.org/10.1007/s10434-999-0290-2openalex-snapshot
Prognostic Value of Laurén Classification and c-erbB-2 Oncogene Overexpression in Adenocarcinoma of the Esophagus and Gastroesophageal Junction
inferredcites →https://doi.org/10.1007/s10620-005-9057-1openalex-snapshot
HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer
inferredcites →https://doi.org/10.1016/0014-2964(69)90077-2openalex-snapshot
Combination of arabinosyl cytosine, methylglyoxal bis (guanylhydrazone), 6-mercaptopurine and prednisone in the treatment of acute myelocytic leukemia
inferredcites →https://doi.org/10.1016/0046-8177(93)90236-aopenalex-snapshot
Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells
inferredcites →https://doi.org/10.1016/0090-8258(92)90103-popenalex-snapshot
HER-2/neu expression: A major prognostic factor in endometrial cancer
inferredcites →https://doi.org/10.1016/j.ctrv.2004.01.001openalex-snapshot
Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches
inferredcites →https://doi.org/10.1016/j.surg.2007.06.006openalex-snapshot
E-cadherin and hereditary diffuse gastric cancer
inferredcites →https://doi.org/10.1016/s0016-5085(97)70071-4openalex-snapshot
Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection
inferredcites →https://doi.org/10.1016/s0016-5085(98)82716-9openalex-snapshot
Prognostic value of Lauren classification and C-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastro-esophageal junction
inferredcites →https://doi.org/10.1016/s0140-6736(07)60028-2openalex-snapshot
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
inferredcites →https://doi.org/10.1016/s0895-4356(02)00534-6openalex-snapshot
Gastric cancer epidemiology and risk factors
inferredcites →https://doi.org/10.1016/s0960-7404(00)00016-5openalex-snapshot
The use of molecular biology in diagnosis and prognosis of gastric cancer
inferredcites →https://doi.org/10.1016/s1091-255x(00)80095-5openalex-snapshot
Analysis of 154 actual five-year survivors of gastric cancer
inferredcites →https://doi.org/10.1038/bjc.1991.243openalex-snapshot
Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer
inferredcites →https://doi.org/10.1038/modpathol.3800712openalex-snapshot
Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus
inferredcites →https://doi.org/10.1038/modpathol.3880288openalex-snapshot
Breast Cancer in the 21st Century: Neu Opportunities and Neu Challenges
inferredcites →https://doi.org/10.1038/modpathol.3880350openalex-snapshot
Protein Overexpression and Gene Amplification of c-erbB-2 in Pulmonary Carcinomas: A Comparative Immunohistochemical and Fluorescence In Situ Hybridization Study
inferredcites →https://doi.org/10.1053/hupa.2001.23511openalex-snapshot
Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study
inferredcites →https://doi.org/10.1056/nejm200103153441101openalex-snapshot
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
inferredcites →https://doi.org/10.1056/nejmoa010187openalex-snapshot
Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction
inferredcites →https://doi.org/10.1056/nejmoa055531openalex-snapshot
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
inferredcites →https://doi.org/10.1093/annonc/mdi064openalex-snapshot
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
inferredcites →https://doi.org/10.1093/jnci/77.5.1047openalex-snapshot
Expression of Epidermal Growth Factor Receptors on Normal Human Gastric Epithelia and Gastric Carcinomas
inferredcites →https://doi.org/10.1097/00019606-200109000-00001openalex-snapshot
Her-2/ neu and Breast Cancer
inferredcites →https://doi.org/10.1111/j.1365-3083.1994.tb03401.xopenalex-snapshot
Significance of erb B‐2 Gene Product as a Target Molecule for Cancer Therapy
inferredcites →https://doi.org/10.1126/science.2470152openalex-snapshot
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
inferredcites →https://doi.org/10.1126/science.2999974openalex-snapshot
Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene
inferredcites →https://doi.org/10.1126/science.3012781openalex-snapshot
The Product of the Human c- erb B-2 Gene: a 185-Kilodalton Glycoprotein with Tyrosine Kinase Activity
inferredcites →https://doi.org/10.1186/1471-2407-6-123openalex-snapshot
HER 2/neu protein expression in colorectal cancer
inferredcites →https://doi.org/10.1186/1471-2407-8-123openalex-snapshot
Clinicopathologic significance of HIF-1α, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer
inferredcites →https://doi.org/10.1200/jco.2000.18.11.2201openalex-snapshot
c-erbB-2 Is of Independent Prognostic Relevance in Gastric Cancer and Is Associated With the Expression of Tumor-Associated Protease Systems
inferredcites →https://doi.org/10.1200/jco.2004.22.14_suppl.4053openalex-snapshot
Expression of HER2 in gastric cancer: Comparison between protein expression and gene amplification using a new commercial kit
inferredcites →https://doi.org/10.1200/jco.2005.05.0245openalex-snapshot
Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data
inferredcites →https://doi.org/10.1200/jco.2006.24.18_suppl.4089openalex-snapshot
Correlation between HER2/neu overexpression/amplification and clinicopathologic parameters in advanced gastric cancer (AGC) patients (pts): A prospective study
inferredcites →https://doi.org/10.1200/jco.2007.25.18_suppl.4613openalex-snapshot
Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification
inferredcites →https://doi.org/10.1245/aso.2003.05.010openalex-snapshot
Clinical Significance of the Epidermal Growth Factor Receptor and HER2 Receptor in Resectable Gastric Cancer
inferredcites →https://doi.org/10.3748/wjg.v12.i2.204openalex-snapshot
Chemotherapy for gastric cancer
inferredcites →https://doi.org/10.3892/ijo.26.6.1525openalex-snapshot
Cox-2 and Her2/neu co-expression in invasive bladder cancer
inferredcites →https://doi.org/10.3892/ijo.27.3.681openalex-snapshot
Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4055520openalex-extracted
Evaluation of Epidermal Growth Factor Receptor 2 Status in Gastric Cancer by Computer Tomography-Based Deep Learning Radiomics Nomogram
inferred← citeshttps://doi.org/10.2139/ssrn.4117355openalex-extracted
inferred← citeshttps://doi.org/10.5281/zenodo.801824openalex-extracted
Some Novel Ways Of Gastric Cancer Patients Treatment Personification
inferred← citeshttps://doi.org/10.1001/jamaoncol.2016.3358openalex-snapshot
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2021.8196openalex-snapshot
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1002/9781118512074.ch31openalex-snapshot
Neoplasia of the Gastrointestinal Tract
inferred← citeshttps://doi.org/10.1002/9781119341154.ch21openalex-snapshot
Gastric Cancer
inferred← citeshttps://doi.org/10.1002/9781119432487.ch1openalex-snapshot
Genomic Strategies for Personalized Cancer Therapy
inferred← citeshttps://doi.org/10.1002/9781119564690.ch5openalex-snapshot
Drug Targets for Biologics
inferred← citeshttps://doi.org/10.1002/adfm.202209393openalex-snapshot
Surface‐Engineered Extracellular Vesicles with CDH17 Nanobodies to Efficiently Deliver Imaging Probes and Chemo‐Photothermal Drugs for Gastric Cancer Theragnostic
inferred← citeshttps://doi.org/10.1002/adfm.202306676openalex-snapshot
Bioprinted Organoids Platform with Tumor Vasculature for Implementing Precision Personalized Medicine Targeted Towards Gastric Cancer
inferred← citeshttps://doi.org/10.1002/adhm.202100966openalex-snapshot
Precise Targeting Therapy of Orthotopic Gastric Carcinoma by siRNA and Chemotherapeutic Drug Codelivered in pH‐Sensitive Nano Platform
inferred← citeshttps://doi.org/10.1002/advs.202102414openalex-snapshot
An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers
inferred← citeshttps://doi.org/10.1002/cam4.230openalex-snapshot
HER 2 and GATA 4 are new prognostic factors for early‐stage ovarian granulosa cell tumor—a long‐term follow‐up study
inferred← citeshttps://doi.org/10.1002/cam4.5722openalex-snapshot
Real‐world clinical outcomes of the combination of anti‐PD ‐1 antibody, trastuzumab, and chemotherapy for HER2 ‐positive gastric/gastroesophageal junction cancer
inferred← citeshttps://doi.org/10.1002/cam4.5893openalex-snapshot
Phase II study ( KAMELEON ) of single‐agent T‐DM1 in patients with HER2 ‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma
inferred← citeshttps://doi.org/10.1002/ccr3.2056openalex-snapshot
A remarkable clinical response in advanced gastric cancer treated with trastuzumab plus capecitabine combination chemotherapy: A report of two cases
inferred← citeshttps://doi.org/10.1002/cncr.30869openalex-snapshot
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium
inferred← citeshttps://doi.org/10.1002/cnr2.2099openalex-snapshot
The ratio of intratumoral CD15 + neutrophils to CD8 + lymphocytes predicts recurrence in patients with gastric cancer after curative resection
inferred← citeshttps://doi.org/10.1002/ctm2.148openalex-snapshot
Pyrotinib combined with CDK4/6 inhibitor in HER2‐positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients
inferred← citeshttps://doi.org/10.1002/cyto.a.23872openalex-snapshot
Single‐Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics
inferred← citeshttps://doi.org/10.1002/dc.23212openalex-snapshot
HER 2 testing in malignant effusions of metastatic gastric carcinoma: Is it feasible?
inferred← citeshttps://doi.org/10.1002/hed.24350openalex-snapshot
Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma
inferred← citeshttps://doi.org/10.1002/ijc.24699openalex-snapshot
Identification of novel hub genes associated with liver metastasis of gastric cancer
inferred← citeshttps://doi.org/10.1002/ijc.26292openalex-snapshot
Clinicopathologic factors associated with HER2‐positive gastric cancer and its impact on survival outcomes—A systematic review
inferred← citeshttps://doi.org/10.1002/ijc.26396openalex-snapshot
mTOR as a therapeutic target in patients with gastric cancer
inferred← citeshttps://doi.org/10.1002/ijc.29159openalex-snapshot
HER2‐positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy
inferred← citeshttps://doi.org/10.1002/ijc.29168openalex-snapshot
The sensitivity of gastric cancer to trastuzumab is regulated by the mi R ‐223/ FBXW 7 pathway
inferred← citeshttps://doi.org/10.1002/ijc.30870openalex-snapshot
DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 resistance
inferred← citeshttps://doi.org/10.1002/ijc.32313openalex-snapshot
EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2‐mediated MAPK pathway activation in gastric cancer cells and avatar mice
inferred← citeshttps://doi.org/10.1002/jcb.28169openalex-snapshot
Genome‐wide analysis of ETV1 targets: Insights into the role of ETV1 in tumor progression
inferred← citeshttps://doi.org/10.1002/jcc.70382openalex-snapshot
Statistical Protein–Protein Interaction Analysis of HER2 ‐Pertuzumab Complex by the Fragment Molecular Orbital Method
inferred← citeshttps://doi.org/10.1002/jgm.3027openalex-snapshot
Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti‐Her2 chimeric antigen receptor gene
inferred← citeshttps://doi.org/10.1002/jso.22024openalex-snapshot
Mesothelin expression correlates with prolonged patient survival in gastric cancer
inferred← citeshttps://doi.org/10.1002/jso.23141openalex-snapshot
Tumor size predicts survival in mucinous gastric carcinoma
inferred← citeshttps://doi.org/10.1002/jso.23456openalex-snapshot
HER2 in resected gastric cancer: Is there prognostic value?
inferred← citeshttps://doi.org/10.1002/jso.24648openalex-snapshot
Down‐regulated miRs specifically correlate with non‐cardial gastric cancers and Lauren's classification system
inferred← citeshttps://doi.org/10.1002/jso.25097openalex-snapshot
MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis
inferred← citeshttps://doi.org/10.1002/jso.26874openalex-snapshot
Molecular pathogenesis and emerging targets of gastric adenocarcinoma
inferred← citeshttps://doi.org/10.1002/jso.27060openalex-snapshot
Fifty years of progress in gastric cancer
inferred← citeshttps://doi.org/10.1002/mc.22514openalex-snapshot
Genome‐wide analysis of DNA copy number alterations in early and advanced gastric cancers
inferred← citeshttps://doi.org/10.1002/onco.13826openalex-snapshot
Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study ( EVIDENCE )
inferred← citeshttps://doi.org/10.1002/path.4269openalex-snapshot
Biomarkers of drugs targeting HER ‐family signalling in cancer
inferred← citeshttps://doi.org/10.1002/path.4679openalex-snapshot
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR , FOCUS and PICCOLO colorectal cancer trials
inferred← citeshttps://doi.org/10.1002/path.5898openalex-snapshot
Artificial intelligence to identify genetic alterations in conventional histopathology
inferred← citeshttps://doi.org/10.1002/ptr.3210openalex-snapshot
Activation of AMP‐activated protein kinase on human gastric cancer cells by apoptosis induced by corosolic acid isolated from Weigela subsessilis
inferred← citeshttps://doi.org/10.1007/13905_2021_4openalex-snapshot
Stomach: The Standard of Care ± HER2
inferred← citeshttps://doi.org/10.1007/7653_2014_26openalex-snapshot
Tissue-Based Companion Diagnostics: Development of IHC Assays from an Industry Perspective
inferred← citeshttps://doi.org/10.1007/978-1-0716-5420-0_8openalex-snapshot
Protein–Protein Interactions Analyzed by the Fragment Molecular Orbital Method
inferred← citeshttps://doi.org/10.1007/978-1-4419-1623-5_61openalex-snapshot
Esophageal Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4614-6015-2_2openalex-snapshot
Targeted Therapies and Molecular Diagnostics of Gastrointestinal Cancers
inferred← citeshttps://doi.org/10.1007/978-1-4614-6015-2_5openalex-snapshot
Molecular Mechanisms and Pathology of Gastric Carcinogenesis: Sporadic Cancers
inferred← citeshttps://doi.org/10.1007/978-1-4939-7734-5_5openalex-snapshot
Target Therapy for Esophageal Adenocarcinoma
inferred← citeshttps://doi.org/10.1007/978-1-60761-806-5_1openalex-snapshot
Applications of Tissue Microarray Technology
inferred← citeshttps://doi.org/10.1007/978-1-61779-358-5_7openalex-snapshot
Gene Signatures in Gastric Cancer
inferred← citeshttps://doi.org/10.1007/978-1-62703-456-2_7openalex-snapshot
Using Genomic Biomarkers to Predict Patient Prognosis and Treatment Response in Gastric Cancer
inferred← citeshttps://doi.org/10.1007/978-2-8178-0527-6_17openalex-snapshot
Indications et gestion des effets secondaires
inferred← citeshttps://doi.org/10.1007/978-3-030-04861-7_10openalex-snapshot
From Molecular Classification to Targeted Therapy for Gastric Cancer in the Precision Medicine Era
inferred← citeshttps://doi.org/10.1007/978-3-030-04861-7_13openalex-snapshot
Nanomedicine in Gastric Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-30192-7_78openalex-snapshot
Esophageal Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-31471-2_3openalex-snapshot
Esophageal and Gastric Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-73158-8_28openalex-snapshot
Target Therapy and Immunotherapy in Gastric Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-87308-0_10openalex-snapshot
Gastrointestinal System Cancers
inferred← citeshttps://doi.org/10.1007/978-3-031-80189-1_16openalex-snapshot
Cutting-Edge Technological Developments in the Diagnosis and Treatment of Malignant Gastric Neoplasm
inferred← citeshttps://doi.org/10.1007/978-3-032-26764-1_28openalex-snapshot
Tissue-Based Diagnostic Techniques in Cutaneous Metastases: Immunohistochemistry, Molecular Pathology, and Cytogenetics
inferred← citeshttps://doi.org/10.1007/978-3-319-15826-6_3openalex-snapshot
Molecular Mechanisms in Gastric Carcinogenesis
inferred← citeshttps://doi.org/10.1007/978-3-319-28776-8_10openalex-snapshot
Molecular Markers in the Prediction of Response to Neoadjuvant Treatments in Esophagogastric Junction Adenocarcinoma
inferred← citeshttps://doi.org/10.1007/978-3-319-46091-8_1openalex-snapshot
Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells
inferred← citeshttps://doi.org/10.1007/978-3-319-79114-2_14openalex-snapshot
Chemical Therapy
inferred← citeshttps://doi.org/10.1007/978-3-319-79114-2_5openalex-snapshot
Clinical Molecular Pathology
inferred← citeshttps://doi.org/10.1007/978-3-319-90761-1_78-1openalex-snapshot
Esophageal Cancer
inferred← citeshttps://doi.org/10.1007/978-3-642-03808-2_6openalex-snapshot
Genetische Aberration, Genexpressionprofile und Epigenetik
inferred← citeshttps://doi.org/10.1007/978-3-642-54676-1_318-1openalex-snapshot
Magenkarzinom
inferred← citeshttps://doi.org/10.1007/978-981-10-4726-8_4openalex-snapshot
Label-Free Biosensors for Early Diagnosis of Cancer Based on G-Quadruplex and Isothermal Amplification
inferred← citeshttps://doi.org/10.1007/978-981-10-6469-2_4openalex-snapshot
Molecular Diagnosis and Targeted Therapy for Gastric Cancer
inferred← citeshttps://doi.org/10.1007/978-981-13-1486-5_3openalex-snapshot
The Clinical and Biological Significance of Tyrosine Kinases in Gastric Cancer
inferred← citeshttps://doi.org/10.1007/978-981-15-4431-6_11openalex-snapshot
Genetic Marker Identification for the Detection of Early-Onset Gastric Cancer Through Genome-Wide Association Studies
inferred← citeshttps://doi.org/10.1007/978-981-15-5471-1_8openalex-snapshot
Recent Development in the Biomarkers for the Gastric Cancer
inferred← citeshttps://doi.org/10.1007/978-981-97-3001-8_7openalex-snapshot
Biosimilars in Gastric Cancer
inferred← citeshttps://doi.org/10.1007/978-981-99-6105-4_13openalex-snapshot
Nanomaterials for Precision Medicine
inferred← citeshttps://doi.org/10.1007/s00108-013-3381-xopenalex-snapshot
Standards der Diagnostik und Therapie des Magenkarzinoms
inferred← citeshttps://doi.org/10.1007/s00109-025-02574-5openalex-snapshot
CD8 + T Cells in Gastrointestinal Cancer: a Perspective on Targeting MicroRNA
inferred← citeshttps://doi.org/10.1007/s00259-020-04898-5openalex-snapshot
Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring
inferred← citeshttps://doi.org/10.1007/s00262-012-1249-xopenalex-snapshot
Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells
inferred← citeshttps://doi.org/10.1007/s00268-010-0467-7openalex-snapshot
Palliative Resection in Noncurative Gastric Cancer Patients
inferred← citeshttps://doi.org/10.1007/s00268-013-2256-6openalex-snapshot
HER2 Expression in Carcinomas of the True Cardia (Siewert Type II Esophagogastric Junction Carcinoma)
inferred← citeshttps://doi.org/10.1007/s00280-014-2400-5openalex-snapshot
Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer
inferred← citeshttps://doi.org/10.1007/s00280-015-2811-yopenalex-snapshot
Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer
inferred← citeshttps://doi.org/10.1007/s00280-016-3013-yopenalex-snapshot
A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer
inferred← citeshttps://doi.org/10.1007/s00280-017-3510-7openalex-snapshot
A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab
inferred← citeshttps://doi.org/10.1007/s00280-018-3753-yopenalex-snapshot
Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer
inferred← citeshttps://doi.org/10.1007/s00280-021-04303-4openalex-snapshot
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells
inferred← citeshttps://doi.org/10.1007/s00292-009-1242-0openalex-snapshot
Grauzonenlymphome
inferred← citeshttps://doi.org/10.1007/s00292-016-0179-3openalex-snapshot
HER2-Testung beim Magenkarzinom
inferred← citeshttps://doi.org/10.1007/s00384-022-04162-2openalex-snapshot
Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study
inferred← citeshttps://doi.org/10.1007/s00428-011-1058-1openalex-snapshot
Inflammation in gastric adenocarcinoma of the cardia: how do EBV infection, Her2 amplification and cancer progression influence tumor-infiltrating lymphocytes?
inferred← citeshttps://doi.org/10.1007/s00428-013-1517-yopenalex-snapshot
FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation
inferred← citeshttps://doi.org/10.1007/s00428-013-1533-yopenalex-snapshot
Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?
inferred← citeshttps://doi.org/10.1007/s00428-018-2354-9openalex-snapshot
Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications
inferred← citeshttps://doi.org/10.1007/s00428-025-04285-1openalex-snapshot
HER2 aberration is a potential predictive biomarker for extrapulmonary small cell neuroendocrine carcinoma contrary to small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s00432-009-0573-9openalex-snapshot
Expression of anion exchanger 1 is associated with tumor progress in human gastric cancer
inferred← citeshttps://doi.org/10.1007/s00432-014-1850-9openalex-snapshot
IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status
inferred← citeshttps://doi.org/10.1007/s00432-014-1900-3openalex-snapshot
HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison
inferred← citeshttps://doi.org/10.1007/s00432-016-2143-2openalex-snapshot
Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin)
inferred← citeshttps://doi.org/10.1007/s00432-017-2374-xopenalex-snapshot
HER2 testing in gastric cancer: results of a German expert meeting
inferred← citeshttps://doi.org/10.1007/s00432-021-03902-1openalex-snapshot
Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer
inferred← citeshttps://doi.org/10.1007/s00432-022-03966-7openalex-snapshot
KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer
inferred← citeshttps://doi.org/10.1007/s00432-023-04689-zopenalex-snapshot
Heat shock protein 90 (HSP90) inhibitors in gastrointestinal cancer: where do we currently stand?—A systematic review
inferred← citeshttps://doi.org/10.1007/s00439-009-0722-xopenalex-snapshot
Nature meets nurture: molecular genetics of gastric cancer
inferred← citeshttps://doi.org/10.1007/s00464-009-0375-9openalex-snapshot
Author reply to the letter to the Editor “Robotic D2 surgery for gastric cancer”
inferred← citeshttps://doi.org/10.1007/s00464-009-0793-8openalex-snapshot
Increased mRNA expression of epidermal growth factor receptor, human epidermal receptor, and survivin in human gastric cancer after the surgical stress of laparotomy versus carbon dioxide pneumoperitoneum in a murine model
inferred← citeshttps://doi.org/10.1007/s00464-018-6138-8openalex-snapshot
Clinicopathological features and endoscopic findings of HER2-positive gastric cancer
inferred← citeshttps://doi.org/10.1007/s00508-011-0025-9openalex-snapshot
Prognostic significance of HER2/neu expression in gastric cancer
inferred← citeshttps://doi.org/10.1007/s00508-011-0078-9openalex-snapshot
Relation between transforming growth factor-β1 expression, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers
inferred← citeshttps://doi.org/10.1007/s00595-010-4370-5openalex-snapshot
Genomic and epigenetic profiles of gastric cancer: Potential diagnostic and therapeutic applications
inferred← citeshttps://doi.org/10.1007/s00595-022-02515-6openalex-snapshot
A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer
inferred← citeshttps://doi.org/10.1007/s00726-011-1096-7openalex-snapshot
In vivo targeting of HER2-positive tumor using 2-helix affibody molecules
inferred← citeshttps://doi.org/10.1007/s00795-013-0037-9openalex-snapshot
Immunohistochemical analysis of invasive micropapillary carcinoma pattern in four cases of gastric cancer
inferred← citeshttps://doi.org/10.1007/s10120-012-0179-9openalex-snapshot
Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment
inferred← citeshttps://doi.org/10.1007/s10120-013-0236-zopenalex-snapshot
Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors
inferred← citeshttps://doi.org/10.1007/s10120-013-0244-zopenalex-snapshot
Effects of a human compact anti-ErbB2 antibody on gastric cancer
inferred← citeshttps://doi.org/10.1007/s10120-014-0362-2openalex-snapshot
Prognostic impact of venous invasion in stage IB node-negative gastric cancer
inferred← citeshttps://doi.org/10.1007/s10120-014-0398-3openalex-snapshot
HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial)
inferred← citeshttps://doi.org/10.1007/s10120-014-0402-yopenalex-snapshot
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
inferred← citeshttps://doi.org/10.1007/s10120-014-0432-5openalex-snapshot
HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study
inferred← citeshttps://doi.org/10.1007/s10120-014-0453-0openalex-snapshot
HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance
inferred← citeshttps://doi.org/10.1007/s10120-015-0471-6openalex-snapshot
Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients
inferred← citeshttps://doi.org/10.1007/s10120-015-0493-0openalex-snapshot
RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases
inferred← citeshttps://doi.org/10.1007/s10120-015-0504-1openalex-snapshot
Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications
inferred← citeshttps://doi.org/10.1007/s10120-015-0545-5openalex-snapshot
MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer
inferred← citeshttps://doi.org/10.1007/s10120-015-0567-zopenalex-snapshot
Phase II trial of dacomitinib in patients with HER2-positive gastric cancer
inferred← citeshttps://doi.org/10.1007/s10120-015-0585-xopenalex-snapshot
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy
inferred← citeshttps://doi.org/10.1007/s10120-016-0599-zopenalex-snapshot
Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer
inferred← citeshttps://doi.org/10.1007/s10120-016-0639-8openalex-snapshot
Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer
inferred← citeshttps://doi.org/10.1007/s10120-017-0729-2openalex-snapshot
Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer
inferred← citeshttps://doi.org/10.1007/s10120-017-0758-xopenalex-snapshot
In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients
inferred← citeshttps://doi.org/10.1007/s10120-018-0887-xopenalex-snapshot
Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
inferred← citeshttps://doi.org/10.1007/s10120-019-00958-4openalex-snapshot
A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
inferred← citeshttps://doi.org/10.1007/s10120-019-00988-yopenalex-snapshot
Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT
inferred← citeshttps://doi.org/10.1007/s10120-020-01039-7openalex-snapshot
Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
inferred← citeshttps://doi.org/10.1007/s10120-020-01045-9openalex-snapshot
Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data
inferred← citeshttps://doi.org/10.1007/s10120-021-01164-xopenalex-snapshot
Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
inferred← citeshttps://doi.org/10.1007/s10120-021-01176-7openalex-snapshot
WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers
inferred← citeshttps://doi.org/10.1007/s10120-021-01182-9openalex-snapshot
Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
inferred← citeshttps://doi.org/10.1007/s10120-022-01298-6openalex-snapshot
Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab
inferred← citeshttps://doi.org/10.1007/s10120-023-01374-5openalex-snapshot
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study
inferred← citeshttps://doi.org/10.1007/s10120-023-01417-xopenalex-snapshot
Down-regulation of stimulator of interferon genes (STING) expression and CD8+ T-cell infiltration depending on HER2 heterogeneity in HER2-positive gastric cancer
inferred← citeshttps://doi.org/10.1007/s10120-025-01699-3openalex-snapshot
Leptomeningeal carcinomatosis in gastric cancer: a single-center retrospective analysis of 86 cases
inferred← citeshttps://doi.org/10.1007/s10120-025-01703-wopenalex-snapshot
Antibody–drug conjugates in gastric cancer: clinical advances and resistance mechanisms
inferred← citeshttps://doi.org/10.1007/s10120-026-01736-9openalex-snapshot
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer
inferred← citeshttps://doi.org/10.1007/s10147-013-0542-9openalex-snapshot
Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer
inferred← citeshttps://doi.org/10.1007/s10269-010-1901-zopenalex-snapshot
Détermination de HER2 dans les adénocarcinomes pour établir le pronostic et prédire la réponse aux traitements
inferred← citeshttps://doi.org/10.1007/s10330-011-0797-4openalex-snapshot
Molecular targeted therapy in gastrointestinal cancer
inferred← citeshttps://doi.org/10.1007/s10330-011-0800-0openalex-snapshot
Predictive biomarker and clinicopathological characteristics analysis for recurrence of early gastric cancer
inferred← citeshttps://doi.org/10.1007/s10353-016-0389-1openalex-snapshot
Targeted therapy in gastric cancer
inferred← citeshttps://doi.org/10.1007/s10495-015-1164-7openalex-snapshot
A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells
inferred← citeshttps://doi.org/10.1007/s10549-013-2410-8openalex-snapshot
Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines
inferred← citeshttps://doi.org/10.1007/s10549-016-3968-8openalex-snapshot
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer
inferred← citeshttps://doi.org/10.1007/s10620-012-2357-3openalex-snapshot
Are Biopsy Specimens Predictive of HER2 Status in Gastric Cancer Patients?
inferred← citeshttps://doi.org/10.1007/s10620-015-3793-7openalex-snapshot
Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling
inferred← citeshttps://doi.org/10.1007/s10620-017-4647-2openalex-snapshot
Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival
inferred← citeshttps://doi.org/10.1007/s10637-014-0173-7openalex-snapshot
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer
inferred← citeshttps://doi.org/10.1007/s11010-013-1850-0openalex-snapshot
The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell
inferred← citeshttps://doi.org/10.1007/s11030-021-10304-5openalex-snapshot
Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK—HER2 and VEGFR2 receptors, by in silico approach
inferred← citeshttps://doi.org/10.1007/s11095-019-2702-8openalex-snapshot
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
inferred← citeshttps://doi.org/10.1007/s11427-016-0034-1openalex-snapshot
Genomic landscape of gastric cancer: molecular classification and potential targets
inferred← citeshttps://doi.org/10.1007/s11523-015-0390-9openalex-snapshot
RETRACTED ARTICLE: MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8
inferred← citeshttps://doi.org/10.1007/s11523-016-0470-5openalex-snapshot
Retraction Note to: MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8
inferred← citeshttps://doi.org/10.1007/s11523-024-01079-4openalex-snapshot
Trastuzumab-Deruxtecan: Redefining HER2 as a Tumor Agnostic Biomarker
inferred← citeshttps://doi.org/10.1007/s11523-024-01097-2openalex-snapshot
Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics
inferred← citeshttps://doi.org/10.1007/s11605-015-2888-yopenalex-snapshot
Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers
inferred← citeshttps://doi.org/10.1007/s11748-015-0575-2openalex-snapshot
Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction
inferred← citeshttps://doi.org/10.1007/s11825-016-0116-0openalex-snapshot
Personalisierte Medizin bei soliden Tumoren
inferred← citeshttps://doi.org/10.1007/s11834-010-0027-3openalex-snapshot
Détermination de HER2 dans les adénocarcinomes pour établir le pronostic et prédire la réponse aux traitements
inferred← citeshttps://doi.org/10.1007/s11864-021-00893-6openalex-snapshot
Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials
inferred← citeshttps://doi.org/10.1007/s11912-016-0525-xopenalex-snapshot
Personalised Treatment in Gastric Cancer: Myth or Reality?
inferred← citeshttps://doi.org/10.1007/s11912-019-0820-4openalex-snapshot
Updates on Management of Gastric Cancer
inferred← citeshttps://doi.org/10.1007/s12013-011-9286-1openalex-snapshot
Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens
inferred← citeshttps://doi.org/10.1007/s12029-017-9921-1openalex-snapshot
Prevalence of HER2 Positivity and Its Clinicopathological Correlation in Locally Advanced/Metastatic Gastric Cancer Patients in Malaysia
inferred← citeshttps://doi.org/10.1007/s12029-018-0162-8openalex-snapshot
Significance of HER2 and Ki-67 in Preneoplastic Lesions and Carcinoma of Gallbladder
inferred← citeshttps://doi.org/10.1007/s12029-025-01239-3openalex-snapshot
Adjuvant Chemotherapy for Gastric Cancer may Worsen Prognosis in Elderly Women: Retrospective Analysis of Individual Patient Data from the CLASSIC Study
inferred← citeshttps://doi.org/10.1007/s12032-012-0357-yopenalex-snapshot
The prognostic significance of p21 and Her-2 gene expression and mutation/polymorphism in patients with gastric adenocarcinoma
inferred← citeshttps://doi.org/10.1007/s12032-013-0464-4openalex-snapshot
Metastatic gastric cancer treatment: a little slow but worthy progress
inferred← citeshttps://doi.org/10.1007/s12032-014-0280-5openalex-snapshot
Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma
inferred← citeshttps://doi.org/10.1007/s12033-026-01611-zopenalex-snapshot
Quantifying HER-2 for Precision Oncology: The Role of Optical Biosensors
inferred← citeshttps://doi.org/10.1007/s12094-009-0396-9openalex-snapshot
Recommendations on current approach to gastric cancer
inferred← citeshttps://doi.org/10.1007/s12094-009-0421-zopenalex-snapshot
Clinical relevance associated to the analysis of circulating tumour cells in patients with solid tumours
inferred← citeshttps://doi.org/10.1007/s12094-011-0637-6openalex-snapshot
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer
inferred← citeshttps://doi.org/10.1007/s12094-011-0702-1openalex-snapshot
SEOM clinical guidelines for using molecular markers in clinical practice
inferred← citeshttps://doi.org/10.1007/s12094-012-0836-9openalex-snapshot
SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma
inferred← citeshttps://doi.org/10.1007/s12094-016-1523-zopenalex-snapshot
Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis
inferred← citeshttps://doi.org/10.1007/s12094-017-1629-yopenalex-snapshot
Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas
inferred← citeshttps://doi.org/10.1007/s12094-017-1711-5openalex-snapshot
An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis
inferred← citeshttps://doi.org/10.1007/s12094-021-02760-0openalex-snapshot
Current status and future perspectives in HER2 positive advanced gastric cancer
inferred← citeshttps://doi.org/10.1007/s12094-022-02875-yopenalex-snapshot
Characteristics of gut microbiota in patients with gastric cancer by surgery, chemotherapy and lymph node metastasis
inferred← citeshttps://doi.org/10.1007/s12094-023-03297-0openalex-snapshot
Clinical significance of CD166 and HER-2 in different types of gastric cancer
inferred← citeshttps://doi.org/10.1007/s12094-025-04155-xopenalex-snapshot
Silencing of MAT2A inhibits gastric cancer cell proliferation, migration, and invasion through activation of the p53 pathway
inferred← citeshttps://doi.org/10.1007/s12105-016-0775-9openalex-snapshot
Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma
inferred← citeshttps://doi.org/10.1007/s12253-013-9654-9openalex-snapshot
HER2 in Gastric Cancer: An Immunohistochemical Study on Tissue Microarrays and the Coressponding Whole-Tissue Sections with a Supplemental Fish Study
inferred← citeshttps://doi.org/10.1007/s12253-015-9909-8openalex-snapshot
Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models
showing the first 200 of 1148
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.